ADXN

Addex Therapeutics Ltd

• PUBT·04/30 20:03

  Addex Therapeutics delays annual Form 20-F filing after financial statement completion setback

• Seeking Alpha·04/30 16:16

  Addex Therapeutics reports FY results

• Benzinga·04/30 14:52

  Addex Therapeutics Q4 2025 Earnings Call Transcript

• Benzinga·04/30 07:59

  Addex Therapeutics Q4 EPS $(1.50) Down From $(1.37) YoY, Sales $20.020K Up From $1.719K YoY

• PUBT·04/30 05:28

  Addex Therapeutics publishes 2025 annual report

• PUBT·04/30 05:02

  Addex FY25 net loss widens to CHF 6.7 million; cash falls to CHF 1.6 million

• TipRanks·04/29 09:35

  Addex Therapeutics announces GABAB PAM candidate data

• PUBT·04/29 05:00

  Addex GABAB PAM candidate cuts cough in bleomycin IPF-related chronic cough model

• Benzinga·04/24 12:05

  12 Health Care Stocks Moving In Friday's Pre-Market Session

• NASDAQ·04/23 14:51

  Addex Reports Neurosterix On Track To Complete Phase 1 Trial For Schizophrenia Drug NTX-253

• TipRanks·04/23 09:46

  Addex Therapeutics says spin-out company to complete NTX-253 study in Q2

• PUBT·04/23 04:58

  Addex says Neurosterix Phase 1 trial of NTX-253 for schizophrenia nears completion

• NASDAQ·04/21 09:09

  Addex Reports Strong Anti-Tussive For GABAB PAM Candidate

• PUBT·04/21 04:57

  Addex GABAB PAM candidate shows anti-tussive activity in primate chronic cough model

• Reuters·03/25 20:04

  Addex Therapeutics files Form 3 initial beneficial ownership statement; Chief Medical Officer and director Roger Mills reports 785,976 common shares